Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HORMONE RECEPTOR POSITIVE/ HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) Advanced/Metastatic Breast Cancer In Real World Settings

CompletadoClinicalTrials.gov

ID: NCT05155566Tipo: OBSERVATIONALInicio: 15 de may de 2019Fin estimado: 12 de mar de 2021

Traducción no disponible, mostrando original

Resumen

To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Latin America.

Elegibilidad

Edad mínima: 18 YearsSexo: FEMALE

Criterios de inclusión

Minimum of six months of follow up data since palbociclib initiation.
Oncologist or gynecologist.
Responsible for treating ≥4-10 (depending on country) ABC/MBC patients who meet the eligibility criteria.
Agrees to participate in the study and complete the case report forms (CRFs) within the data collection period.
HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
Received palbociclib as a first line therapy.
No prior or current enrolment in an interventional clinical trial for ABC/MBC.

Criterios de exclusión

Qualified less than 2 years ago or more than 35 years ago.
Participated in observational research for ABC/MBC in the last 3 months.
Have not prescribed either palbociclib plus fulvestrant or palbociclib plus aromatase inhibitor as first line therapy.

Ubicaciones

Pfizer country office

Buenos Aires, Argentina

Patrocinadores

PrincipalPfizer

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Treatment Patterns And Clinical Outcomes Among Patients i... | EligiMed